Literature DB >> 17070667

Cytokine-effects on glucocorticoid receptor function: relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression.

Thaddeus W W Pace1, Fang Hu, Andrew H Miller.   

Abstract

Glucocorticoids play an essential role in the response to environmental stressors, serving initially to mobilize bodily responses to challenge and ultimately serving to restrain neuroendocrine and immune reactions. A number of diseases including autoimmune, infectious and inflammatory disorders as well as certain neuropsychiatric disorders such as major depression have been associated with decreased responsiveness to glucocorticoids (glucocorticoid resistance), which is believed to be related in part to impaired functioning of the glucocorticoid receptor (GR). Glucocorticoid resistance, in turn, may contribute to excessive inflammation as well as hyperactivity of corticotropin releasing hormone and sympathetic nervous system pathways, which are known to contribute to a variety of diseases as well as behavioral alterations. Recent data indicate that glucocorticoid resistance may be a result of impaired GR function secondary to chronic exposure to inflammatory cytokines as may occur during chronic medical illness or chronic stress. Indeed, inflammatory cytokines and their signaling pathways including mitogen-activated protein kinases, nuclear factor-kappaB, signal transducers and activators of transcription, and cyclooxygenase have been found to inhibit GR function. Mechanisms include disruption of GR translocation and/or GR-DNA binding through protein-protein interactions of inflammatory mediators with the GR itself or relevant steroid receptor cofactors as well as alterations in GR phosphorylation status. Interestingly, cAMP signal transduction pathways can enhance GR function and inhibit cytokine signaling. Certain antidepressants have similar effects. Thus, further understanding the effects of cytokines on GR signaling and the mechanisms involved may reveal novel therapeutic targets for reversal of glucocorticoid resistance and restoration of glucocorticoid-mediated inhibition of relevant bodily/immune responses during stress and immune challenge.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17070667      PMCID: PMC1820632          DOI: 10.1016/j.bbi.2006.08.009

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   7.217


  82 in total

Review 1.  Mammalian MAP kinase signalling cascades.

Authors:  L Chang; M Karin
Journal:  Nature       Date:  2001-03-01       Impact factor: 49.962

Review 2.  Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment.

Authors:  C M Pariante; A H Miller
Journal:  Biol Psychiatry       Date:  2001-03-01       Impact factor: 13.382

Review 3.  Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation.

Authors:  J M Kyriakis; J Avruch
Journal:  Physiol Rev       Date:  2001-04       Impact factor: 37.312

4.  Social disruption-induced glucocorticoid resistance: kinetics and site specificity.

Authors:  Ronit Avitsur; Jennifer L Stark; Firdaus S Dhabhar; David A Padgett; John F Sheridan
Journal:  J Neuroimmunol       Date:  2002-03       Impact factor: 3.478

5.  Interleukin-2 inhibits glucocorticoid receptor transcriptional activity through a mechanism involving STAT5 (signal transducer and activator of transcription 5) but not AP-1.

Authors:  A Biola; P Lefebvre; M Perrin-Wolff; M Sturm; J Bertoglio; M Pallardy
Journal:  Mol Endocrinol       Date:  2001-07

6.  Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor.

Authors:  H M Reichardt; J P Tuckermann; M Göttlicher; M Vujic; F Weih; P Angel; P Herrlich; G Schütz
Journal:  EMBO J       Date:  2001-12-17       Impact factor: 11.598

7.  Proinflammatory cytokines regulate human glucocorticoid receptor gene expression and lead to the accumulation of the dominant negative beta isoform: a mechanism for the generation of glucocorticoid resistance.

Authors:  J C Webster; R H Oakley; C M Jewell; J A Cidlowski
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-29       Impact factor: 11.205

8.  p38 Mitogen-activated protein kinase-induced glucocorticoid receptor phosphorylation reduces its activity: role in steroid-insensitive asthma.

Authors:  Elvis Irusen; John G Matthews; Atsushi Takahashi; Peter J Barnes; Kian F Chung; Ian M Adcock
Journal:  J Allergy Clin Immunol       Date:  2002-04       Impact factor: 10.793

9.  Nonsteroidal anti-inflammatory drugs suppress T-cell activation by inhibiting p38 MAPK induction.

Authors:  Silvia Rossi Paccani; Marianna Boncristiano; Cristina Ulivieri; Mario Milco D'Elios; Gianfranco Del Prete; Cosima T Baldari
Journal:  J Biol Chem       Date:  2001-11-07       Impact factor: 5.157

10.  Glucocorticoid receptor signaling in the intestinal epithelial cell lines IEC-6 and Caco-2: evidence of inhibition by interleukin-1beta.

Authors:  D Raddatz; S Toth; H Schwörer; G Ramadori
Journal:  Int J Colorectal Dis       Date:  2001-11       Impact factor: 2.571

View more
  213 in total

1.  Association of anhedonia with recurrent major adverse cardiac events and mortality 1 year after acute coronary syndrome.

Authors:  Karina W Davidson; Matthew M Burg; Ian M Kronish; Daichi Shimbo; Lucia Dettenborn; Roxana Mehran; David Vorchheimer; Lynn Clemow; Joseph E Schwartz; Francois Lespérance; Nina Rieckmann
Journal:  Arch Gen Psychiatry       Date:  2010-05

2.  The concept of depression as a dysfunction of the immune system.

Authors:  Brian E Leonard
Journal:  Curr Immunol Rev       Date:  2010-08

Review 3.  Effects of psychotropic drugs on inflammation: consequence or mediator of therapeutic effects in psychiatric treatment?

Authors:  David Baumeister; Simone Ciufolini; Valeria Mondelli
Journal:  Psychopharmacology (Berl)       Date:  2015-08-14       Impact factor: 4.530

Review 4.  Inflammation: depression fans the flames and feasts on the heat.

Authors:  Janice K Kiecolt-Glaser; Heather M Derry; Christopher P Fagundes
Journal:  Am J Psychiatry       Date:  2015-09-11       Impact factor: 18.112

Review 5.  The Immune System and the Role of Inflammation in Perinatal Depression.

Authors:  Philippe Leff-Gelman; Ismael Mancilla-Herrera; Mónica Flores-Ramos; Carlos Cruz-Fuentes; Juan Pablo Reyes-Grajeda; María Del Pilar García-Cuétara; Marielle Danitza Bugnot-Pérez; David Ellioth Pulido-Ascencio
Journal:  Neurosci Bull       Date:  2016-07-18       Impact factor: 5.203

6.  Caregiving burden, stress, and health effects among family caregivers of adult cancer patients.

Authors:  Margaret Bevans; Esther M Sternberg
Journal:  JAMA       Date:  2012-01-25       Impact factor: 56.272

7.  Transient pretreatment with glucocorticoid ablates innate toxicity of systemically delivered adenoviral vectors without reducing efficacy.

Authors:  Sergey S Seregin; Daniel M Appledorn; Aaron J McBride; Nathaniel J Schuldt; Yasser A Aldhamen; Tyler Voss; Junping Wei; Matthew Bujold; William Nance; Sarah Godbehere; Andrea Amalfitano
Journal:  Mol Ther       Date:  2009-01-27       Impact factor: 11.454

8.  Knockdown of interleukin-1 receptor type-1 on endothelial cells attenuated stress-induced neuroinflammation and prevented anxiety-like behavior.

Authors:  Eric S Wohleb; Jenna M Patterson; Vikram Sharma; Ning Quan; Jonathan P Godbout; John F Sheridan
Journal:  J Neurosci       Date:  2014-02-12       Impact factor: 6.167

9.  Altered mRNA Levels of Glucocorticoid Receptor, Mineralocorticoid Receptor, and Co-Chaperones (FKBP5 and PTGES3) in the Middle Frontal Gyrus of Autism Spectrum Disorder Subjects.

Authors:  Neil Patel; Amanda Crider; Chirayu D Pandya; Anthony O Ahmed; Anilkumar Pillai
Journal:  Mol Neurobiol       Date:  2015-04-26       Impact factor: 5.590

10.  Exaggerated Increases in Microglia Proliferation, Brain Inflammatory Response and Sickness Behaviour upon Lipopolysaccharide Stimulation in Non-Obese Diabetic Mice.

Authors:  Barry McGuiness; Sinead M Gibney; Wouter Beumer; Marjan A Versnel; Inge Sillaber; Andrew Harkin; Hemmo A Drexhage
Journal:  Neuroimmunomodulation       Date:  2016-08-17       Impact factor: 2.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.